➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Mallinckrodt
Harvard Business School
Johnson and Johnson
AstraZeneca
Medtronic

Last Updated: July 6, 2020

DrugPatentWatch Database Preview

TRIGLIDE Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Which patents cover Triglide, and when can generic versions of Triglide launch?

Triglide is a drug marketed by Skyepharma Ag and is included in one NDA. There is one patent protecting this drug.

This drug has forty patent family members in thirteen countries.

The generic ingredient in TRIGLIDE is fenofibrate. There are forty-two drug master file entries for this compound. Fifty-five suppliers are listed for this compound. Additional details are available on the fenofibrate profile page.

US ANDA Litigation and Generic Entry Outlook for Triglide

A generic version of TRIGLIDE was approved as fenofibrate by RHODES PHARMS on May 13th, 2005.

  Start Trial

Drug patent expirations by year for TRIGLIDE
Drug Prices for TRIGLIDE

See drug prices for TRIGLIDE

Drug Sales Revenue Trends for TRIGLIDE

See drug sales revenues for TRIGLIDE

Recent Clinical Trials for TRIGLIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Medical University of South CarolinaPhase 4

See all TRIGLIDE clinical trials

Pharmacology for TRIGLIDE

US Patents and Regulatory Information for TRIGLIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Skyepharma Ag TRIGLIDE fenofibrate TABLET;ORAL 021350-001 May 7, 2005 DISCN No No   Start Trial   Start Trial Y Y   Start Trial
Skyepharma Ag TRIGLIDE fenofibrate TABLET;ORAL 021350-002 May 7, 2005 BX RX Yes No   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Mallinckrodt
Harvard Business School
Johnson and Johnson
AstraZeneca
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.